TrialsgrambêtaRCTs are beautiful
ESC Congress 2026Présenté dim. 30 août · 09:24 UTC+2Hot Line 6Tous les essais Hot Line →

PADN-PH-LHD

2026

A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of Single-use Ring-shaped Pulmonary Artery Radiofrequency Ablation Catheter and Pulmonary Artery RF Ablation Generator for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure

In 264 patients with pulmonary hypertension due to heart failure, pulmonary artery denervation reduced clinical worsening compared with medical therapy alone.

Résultat

Efficacité: Clinical worsening: first occurrence of any of: intravenous inotropes, diuretics or vasodilators for worsening heart failure; rehospitalisation for heart failure; 6-minute walk distance decrease >10 % or >30 m from baseline; referral for heart or heart–lung transplantation; all-cause death, assessed when the last enrolled patient has ≥6 months of follow-upHR 0,49 (IC à 95 % 0,30-0,82) · P = 0,006

En dessous de 1 en faveur de pulmonary artery denervation, au-dessus de 1 en faveur de medical therapy alone.

Taux d’événements
Différence absolue
25,8 points
NNT
4

La différence absolue et le NNT sont dérivés des taux d’événements.

Également rapporté: Kaplan-Meier estimated over a median follow-up of 338 days. Access-site haematoma in 2 of 134 denervation patients and 1 of 130 controls, with no other procedural complications; adverse events during follow-up were similar in both groups.

Publication originale
Sous-thème
Pulmonary artery denervation
Schéma
phase 3 device trial, prospective, multicentre (up to 39 centres in China), randomised 1:1, open-label with blinded outcome assessment; pulmonary artery denervation plus guideline-directed medical therapy vs guideline-directed medical therapy alone (no sham procedure); primary analysis when the last enrolled patient reaches 6 months; follow-up to 3 years; control patients may cross over to PADN at 12 months
Pertinence
Important: l’un des piliers parmi d’autres.
Source
Zhang H, Wang L, Liang X, et al. N Engl J Med. 2026; published online 30 August.doi 10.1056/nejmoa2609056

Discussion et critique

A halving of clinical worsening from a single catheter procedure, in a group with no treatment of its own: pulmonary hypertension from left heart disease is where the pulmonary vasodilators have repeatedly failed, so a positive device trial here is genuinely new. Three things bound it. The median follow-up is 338 days while the estimate quoted is at two years, so the curve's second half rests on few patients; the control arm received a procedure-free comparison, which in a composite carrying outpatient worsening and a walk-distance decline is the weakest part of the design; and the trial is Chinese, single-country, sponsored by the device maker. The effect is large enough to matter and the confirmation should be blinded.